Kosh is a Digital Content Designer with an extensive background in Graphic Design and UX & UI design. He specializies in developing online visual content and supporting various teams across the globe. In his current role he also performs analysis on the customer's journey, to identify the best user experience and enhance engagement.
Latest from Kosh Naran
CBER has at least 14 and CDER another 10 novel biologics among the more than 60 candidates with a user fee goal in 2025.
Despite experiencing significant drops in pharmaceutical revenues in 2023, Pfizer and AbbVie maintained their top positions, ranking first and second respectively, in the latest Scrip 100.
Lilly’s Mounjaro to Pfizer’s Paxlovid, the WuXi group has been part of pharma majors’ sourcing chain. How big is the hole clients are to fill when the proposed BIOSECURE Act comes into effect? Here’s a Scrip infographic using Evaluate Pharma data.
J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.
AI is all the rage these days, so it comes as no surprise that the topic of AI technologies ranked high during the panel discussions at the HLTH Europe event, held from 17-20 June in Amsterdam.
J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.